The UK charity for Waldenstrom’s macroglobulinaemia – a rare type of blood cancer

Support Line: 0300 373 8500

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

A first-in-human study to test the safety and efficacy of a new targeted treatment

Main Aims

This study is testing how safe a new type of targeted treatment is in people with types of lymphoma, including WM.
JNJ-75348780 is a type of drug that targets specific proteins that are known to help cancer cells grow. By stopping these proteins, researchers hope that the cancer cells will stop growing or be killed.

This study is on-going but currently closed to recruitment.

Recruitment Criteria

• Confirmed diagnosis of WM

• WM has come back or not responded to treatment

• No further standard treatment options remaining

Recruitment status: Not Recruiting

Sponsor: Janssen Research & Development, LLC

Expected to end: 31/05/2025

Phases: Phase 1